Evidence map›Paper›PMID 35639875›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Risk Factors for Ebola Virus Persistence in Semen of Survivors in Liberia.

Jonathan Dyal, Aaron Kofman, Jomah Z Kollie, John Fankhauser, Romeo Orone, Moses J Soka, Uriah Glaybo, Armah Kiawu, Edna Freeman, Giovanni Giah and 39 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

49 authors at 9 institutions in 2 countries.

Jonathan DyalEpidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Aaron KofmanEpidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-7507-6355
Jomah Z KollieMen's Health Screening Program, Monrovia, Liberia.
John FankhauserELWA Hospital, Samaritan's Purse, Monrovia, Liberia.
Romeo OroneELWA Hospital, Samaritan's Purse, Monrovia, Liberia.
Moses J SokaELWA Hospital, Samaritan's Purse, Monrovia, Liberia.
Uriah GlayboMen's Health Screening Program, Monrovia, Liberia.
Armah KiawuMen's Health Screening Program, Monrovia, Liberia.
Edna FreemanMen's Health Screening Program, Monrovia, Liberia.
Giovanni GiahMen's Health Screening Program, Monrovia, Liberia.
Henry D TonyMen's Health Screening Program, Monrovia, Liberia.
Mylene FaikaiMen's Health Screening Program, Monrovia, Liberia.
Mary JawaraMen's Health Screening Program, Monrovia, Liberia.
Kuku KamaraMen's Health Screening Program, Monrovia, Liberia.
Samuel KamaraMen's Health Screening Program, Monrovia, Liberia.
Benjamin FlowersMen's Health Screening Program, Monrovia, Liberia.
Mohammed L KromahMen's Health Screening Program, Monrovia, Liberia.
Rodel Desamu-ThorpeOffice of Public Health Preparedness and Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
James GrazianoDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Shelley BrownDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Maria E Morales-BetoulleDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Deborah L CannonDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Kaihong SuDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Susanne L LindermanEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Mateusz PlucinskiDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Eric RogierDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Richard S BradburyDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
W Evan SecorDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Katherine E BowdenDivision of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Christi PhillipsDivision of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Mary N CarringtonBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
Yeon-Hwa ParkBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
Maureen P MartinBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
Maria Del Pilar AguinagaDepartment of Internal Medicine, Meharry Sickle Cell Center, Meharry Medical College, Nashville, Tennessee, USA.
Robert MushiDepartment of Internal Medicine, Meharry Sickle Cell Center, Meharry Medical College, Nashville, Tennessee, USA.
Dana L HaberlingDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Elizabeth D ErvinDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
John D KlenaDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Moses MassaquoiMinistry of Health, Liberia.
Tolbert NyenswahMinistry of Health, Liberia.
Stuart T NicholDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
David E ChiribogaUniversity of Massachusetts Medical School, Worcester, Massachusetts, USA.
Desmond E WilliamsCenter for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Steven H HinrichsDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Rafi AhmedEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Benjamin T VonhmNational Public Health Institute of Liberia, Monrovia, Liberia.
Pierre E RollinDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Lawrence J PurpuraDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Mary J ChoiDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Centers for Disease Control and Prevention · USEmory University · USFrederick National Laboratory for Cancer Research · USMeharry Medical College · USUniversity of Liberia · LRUniversity of Nebraska Medical Center · USNational Public Health Institute of Liberia · LRRagon Institute of MGH, MIT and Harvard · USUniversity of Massachusetts Chan Medical School · US

Funding

The RCMI Program in Health Disparities Research at Meharry Medical College - SupplementU54MD007586 · NIMHD · MEHARRY MEDICAL COLLEGE · PI Samuel Evans Adunyah · 2017 to 2026
$48.2M
Effects of genetic polymorphism in MHC, KIR, and related loci on human diseaseZIABC010791 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$18.2M
Training in Clinical and Epidemiological Research for Liberia (TRACER)U2RTW011281 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARTIN, JEFFREY N · 2019 to 2023
$1.2M
CCR NIH HHS HHSN261200800001CFIC NIH HHS U2R TW011281NCI NIH HHS HHSN261200800001ENIMHD NIH HHS U54 MD007586
6 · The paper itself

Abstract

backgroundLong-term persistence of Ebola virus (EBOV) in immunologically privileged sites has been implicated in recent outbreaks of Ebola virus disease (EVD) in Guinea and the Democratic Republic of Congo. This study was designed to understand how the acute course of EVD, convalescence, and host immune and genetic factors may play a role in prolonged viral persistence in semen.

methodsA cohort of 131 male EVD survivors in Liberia were enrolled in a case-case study. "Early clearers" were defined as those with 2 consecutive negative EBOV semen test results by real-time reverse-transcription polymerase chain reaction (rRT-PCR) ≥2 weeks apart within 1 year after discharge from the Ebola treatment unit or acute EVD. "Late clearers" had detectable EBOV RNA by rRT-PCR >1 year after discharge from the Ebola treatment unit or acute EVD. Retrospective histories of their EVD clinical course were collected by questionnaire, followed by complete physical examinations and blood work.

resultsCompared with early clearers, late clearers were older (median, 42.5 years; P < .001) and experienced fewer severe clinical symptoms (median 2, P = .006). Late clearers had more lens opacifications (odds ratio, 3.9 [95% confidence interval, 1.1-13.3]; P = .03), after accounting for age, higher total serum immunoglobulin G3 (IgG3) titers (P = .005), and increased expression of the HLA-C*03:04 allele (0.14 [.02-.70]; P = .007).

conclusionsOlder age, decreased illness severity, elevated total serum IgG3 and HLA-C*03:04 allele expression may be risk factors for the persistence of EBOV in the semen of EVD survivors. EBOV persistence in semen may also be associated with its persistence in other immunologically protected sites, such as the eye.

Indexed as

EbolavirusHemorrhagic Fever, EbolaHLA-C AntigensHumansLiberiaMaleRetrospective StudiesRisk FactorsSemenSurvivorsHLA-C AntigensEbolapersistencesemen

Identifiers

PMID35639875
PMCPMC10169428
OpenAlexW4281618141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.